Monday, July 25, 2016 7:17:42 PM
2016-07-12 TISSUE TARGETING
Many anti-cancer agents attack cancer cells and normal cells alike. Therapeutic approaches to selectively target cancer tissues while minimizing toxic effects against normal tissues are therefore an important pursuit.
SUMMARY OF THE INVENTION
[0003] The invention is based, at least in part, on the discovery that a low molecular weight heparin described herein (e.g., a LMWH lacking substantial anticoagulant activity, e.g., M402) conjugated to a heterologous agent exhibited selective accumulation at the site of a primary tumor when administered to an experimental animal. Accordingly, the invention features, inter alia, methods to deliver and target an agent, e.g., a therapeutic or imaging agent, to a tumor site in a subject. Also included are related methods to deliver and target an agent, e.g., a therapeutic or imaging agent, to a site of inflammation, fibrosis or infection in a subject.
Read more:
https://worldwide.espacenet.com/publicationDetails/description?CC=BR&NR=112012026542A2&KC=A2&FT=D&ND=3&date=20160712&DB=EPODOC&locale=en_EP
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM